DGAP-News: Newly founded biotech company ActiTrexx receives funding of € 3.5 million to develop cell therapy against transplant rejection

The company develops ATreg, a cell therapy based on activated regulatory T cells that are stimulated using a proprietary process, for the treatment of transplant rejection, primarily in the field of stem cell transplantation, and autoimmune disorders.